Sponsor-Investigators

Robert R. McWilliams

HCRN-MEL16-252

Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252

Status

Open to Accrual

Cancer Types

Melanoma

Locations

Fox Chase Cancer Center, Iowa, Masonic Cancer Center, University of Minnesota, Mayo Clinic, Minnesota, Nebraska, Nebraska Cancer Specialists, Oregon, Pennsylvania, Providence Cancer Institute, University of Iowa Holden Comprehensive Cancer Center